Structure via PubChem · Public domain (PubChem)
ibipinabant
Sign in to saveAlso known as BMS-646256, SLV319
Ibipinabant (SLV319, BMS-646,256) was designed by Jos Lange at Solvay Pharmaceuticals in 2000. Nowadays, it is an in vivo active pharmacological tool used in scientific research which acts as a potent and highly selective CB1 antagonist. It has potent anorectic effects in animals, and was researched for the treatment of obesity, although CB1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagon
Chemical data
- Formula
- C23H20Cl2N4O2S
- Molecular weight
- 487.4 g/mol
- IUPAC name
- (4S)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide
- SMILES
- CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
- InChIKey
- AXJQVVLKUYCICH-OAQYLSRUSA-N
- XLogP
- 5.3
- Polar surface area
- 82.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- obesity, type 2 diabetes mellitus
via ChEMBL · EBI
Wikidata facts
- Mass
- 486.068402
Show 3 more facts
- chemical formula
- C₂₃H₂₀Cl₂N₄O₂S
- isomeric SMILES
- CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
- canonical SMILES
- CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Ibipinabant (SLV319, BMS-646,256) was designed by Jos Lange at Solvay Pharmaceuticals in 2000. Nowadays, it is an in vivo active pharmacological tool used in scientific research which acts as a potent and highly selective CB1 antagonist. It has potent anorectic effects in animals, and was researched for the treatment of obesity, although CB1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagonists. SLV330, which is a structural analogue of Ibipinabant, was reported active in animal models related to the regulation of memory, cognition, as well as in addictive behavior. An atom-efficient synthesis of ibipinabant has been reported.
== See also == Cannabinoid receptor antagonist
Excerpted from Wikipedia’s “ibipinabant” article, available under the CC BY-SA 4.0 licence.